Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2012

01.07.2012 | Clinical trial

Prognostic value of Ki-67 labeling index in patients with node-negative, triple-negative breast cancer

verfasst von: Elisabetta Munzone, E. Botteri, A. Sciandivasci, G. Curigliano, F. Nolè, M. Mastropasqua, N. Rotmensz, M. Colleoni, A. Esposito, L. Adamoli, A. Luini, A. Goldhirsch, G. Viale

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

The aim of this analysis was to investigate the usefulness of Ki-67 labeling index (LI) for the identification of different prognostic subgroups in primary node-negative, triple negative breast cancer (TNBC) patients. From January 1997 to December 2005, 1,053 patients operated for TNBC were identified through the institutional clinical database. The study was performed in accordance with REMARK criteria. The relationship between Ki-67LI and the risk of breast-related deaths was evaluated with a multivariable Cox regression model. Cubic splines were used to model Ki-67LI as a continuous variable. We selected 496 consecutive patients with node-negative TNBC. Median age was 52 years, median Ki-67LI 48 % (range 4–95), and median follow up 6 years (range 0.5–13). Total deaths and deaths from BC were 52 (10.5 %) and 38 (7.7 %), respectively. Ki-67LI increased with decreasing age (P < 0.01), increasing tumor size (P < 0.01), and grade (P < 0.01). When analyzing Ki-67LI as a continuous variable, the risk of death from BC increased steeply with increasing Ki-67LI up to about 35 % and remained flat for higher values (adjusted effect of Ki-67 P = 0.049; adjusted nonlinear effect P = 0.021). Accordingly, when dividing patients into lower (≤35 %) and higher (>35 %) Ki-67LI subgroups, the 5-year cumulative incidence of breast-related deaths were 2.3 and 9.0 %, respectively, with an adjusted HR>35 vs ≤35 of 2.3 (95 % CI 1.0–5.8, P = 0.046). Within the group of patients with node-negative TNBC, Ki-67LI was associated with different prognoses subgroups. Ki-67LI might be useful in the design of trials of risk-adapted adjuvant therapies.
Literatur
1.
Zurück zum Zitat Gluz O, Liedtke C, Gottschalk N et al (2009) Triple negative breast cancer—current status and future directions. Ann Oncol 20:1913–1927PubMedCrossRef Gluz O, Liedtke C, Gottschalk N et al (2009) Triple negative breast cancer—current status and future directions. Ann Oncol 20:1913–1927PubMedCrossRef
2.
Zurück zum Zitat Hudis C, Gianni L (2011) Triple-negative breast cancer: an unmet medical need. Oncologist 16(suppl 1):1–11PubMedCrossRef Hudis C, Gianni L (2011) Triple-negative breast cancer: an unmet medical need. Oncologist 16(suppl 1):1–11PubMedCrossRef
3.
Zurück zum Zitat Adamo B, Anders CK (2011) Stratifying triple-negative breast cancer: which definition(s) to use? Breast Cancer Res 13:105PubMedCrossRef Adamo B, Anders CK (2011) Stratifying triple-negative breast cancer: which definition(s) to use? Breast Cancer Res 13:105PubMedCrossRef
4.
Zurück zum Zitat Cheang MC, Voduc D, Bajdik C et al (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14:1368–1376PubMedCrossRef Cheang MC, Voduc D, Bajdik C et al (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14:1368–1376PubMedCrossRef
5.
Zurück zum Zitat Prat A, Parker J, Karginova O et al (2010) Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 12:R68PubMedCrossRef Prat A, Parker J, Karginova O et al (2010) Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 12:R68PubMedCrossRef
6.
Zurück zum Zitat Urruticoechea A, Smith IE, Dowsett M (2005) Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 23(28):7212–7220PubMedCrossRef Urruticoechea A, Smith IE, Dowsett M (2005) Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 23(28):7212–7220PubMedCrossRef
7.
Zurück zum Zitat Petit T, Wilt M, Velten M et al (2004) Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer 40:205–211PubMedCrossRef Petit T, Wilt M, Velten M et al (2004) Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer 40:205–211PubMedCrossRef
8.
Zurück zum Zitat Pohl G, Rudas M, Taucher S et al (2003) Expression of cell cycle regulatory proteins in breast carcinomas before and after preoperative chemotherapy. Breast Cancer Res Treat 78:97–103PubMedCrossRef Pohl G, Rudas M, Taucher S et al (2003) Expression of cell cycle regulatory proteins in breast carcinomas before and after preoperative chemotherapy. Breast Cancer Res Treat 78:97–103PubMedCrossRef
9.
Zurück zum Zitat Brown RW, Allred CD, Clark GM et al (1996) Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer. Clin Cancer Res 2:585–592PubMed Brown RW, Allred CD, Clark GM et al (1996) Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer. Clin Cancer Res 2:585–592PubMed
10.
Zurück zum Zitat Weikel W, Brumm C, Wilkens C, Beck T, Knapstein PG (1995) Growth fractions (Ki-67) in primary breast cancers, with particular reference to node-negative tumors. Cancer Detect Prev 19:446–450PubMed Weikel W, Brumm C, Wilkens C, Beck T, Knapstein PG (1995) Growth fractions (Ki-67) in primary breast cancers, with particular reference to node-negative tumors. Cancer Detect Prev 19:446–450PubMed
11.
Zurück zum Zitat Rhee J, Han SW, Oh DY et al (2008) The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. BMC Cancer 8:307PubMedCrossRef Rhee J, Han SW, Oh DY et al (2008) The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. BMC Cancer 8:307PubMedCrossRef
12.
Zurück zum Zitat Dowsett M, Nielsen TO, A’hern R et al (2011) Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst 103:1656–1664PubMedCrossRef Dowsett M, Nielsen TO, A’hern R et al (2011) Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst 103:1656–1664PubMedCrossRef
13.
Zurück zum Zitat Hernandez-Aya LF, Chavez-MacGregor M, Lei X et al (2011) Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. J Clin Oncol 29:2628–2634PubMedCrossRef Hernandez-Aya LF, Chavez-MacGregor M, Lei X et al (2011) Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. J Clin Oncol 29:2628–2634PubMedCrossRef
14.
Zurück zum Zitat McShane LM, Altman DG, Sauerbrei W et al (2006) Reporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100:229–235PubMedCrossRef McShane LM, Altman DG, Sauerbrei W et al (2006) Reporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100:229–235PubMedCrossRef
15.
Zurück zum Zitat Rosen PP, Oberman H (1993) Tumors of the mammary gland. Armed Forces Institute of Pathology, Washington, DC Rosen PP, Oberman H (1993) Tumors of the mammary gland. Armed Forces Institute of Pathology, Washington, DC
16.
Zurück zum Zitat Elston CW, Ellis IO (2002) Pathological prognostic factors in breast cancer, I: the value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 41:151PubMedCrossRef Elston CW, Ellis IO (2002) Pathological prognostic factors in breast cancer, I: the value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 41:151PubMedCrossRef
17.
Zurück zum Zitat Gray RJ (1988) A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141–1154CrossRef Gray RJ (1988) A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141–1154CrossRef
18.
Zurück zum Zitat Durrleman S, Simon R (1989) Flexible regression models with cubic splines. Stat Med 8:551–561PubMedCrossRef Durrleman S, Simon R (1989) Flexible regression models with cubic splines. Stat Med 8:551–561PubMedCrossRef
19.
Zurück zum Zitat Dent R, Trudeau M, Pritchard KI et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429–4434PubMedCrossRef Dent R, Trudeau M, Pritchard KI et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429–4434PubMedCrossRef
20.
Zurück zum Zitat Keam B, Im SA, Lee KH et al (2011) Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res 13:R22PubMedCrossRef Keam B, Im SA, Lee KH et al (2011) Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res 13:R22PubMedCrossRef
21.
Zurück zum Zitat Rakha EA, El-Rehim DA, Paish C et al (2006) Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer 42:3149–3156PubMedCrossRef Rakha EA, El-Rehim DA, Paish C et al (2006) Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer 42:3149–3156PubMedCrossRef
22.
Zurück zum Zitat Yamamoto Y, Ibusuki M, Nakano M et al (2009) Clinical significance of basal-like subtype in triple-negative breast cancer. Breast Cancer 16:260–267PubMedCrossRef Yamamoto Y, Ibusuki M, Nakano M et al (2009) Clinical significance of basal-like subtype in triple-negative breast cancer. Breast Cancer 16:260–267PubMedCrossRef
23.
Zurück zum Zitat Munzone E, Curigliano G, Burstein HJ et al (2012) CMF revisited in the 21st century. Ann Oncol 23(2):305–311PubMedCrossRef Munzone E, Curigliano G, Burstein HJ et al (2012) CMF revisited in the 21st century. Ann Oncol 23(2):305–311PubMedCrossRef
24.
25.
Zurück zum Zitat Wirapati P, Sotiriou C, Kunkel S et al (2008) Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 10(4):R65PubMedCrossRef Wirapati P, Sotiriou C, Kunkel S et al (2008) Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 10(4):R65PubMedCrossRef
Metadaten
Titel
Prognostic value of Ki-67 labeling index in patients with node-negative, triple-negative breast cancer
verfasst von
Elisabetta Munzone
E. Botteri
A. Sciandivasci
G. Curigliano
F. Nolè
M. Mastropasqua
N. Rotmensz
M. Colleoni
A. Esposito
L. Adamoli
A. Luini
A. Goldhirsch
G. Viale
Publikationsdatum
01.07.2012
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2012
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-012-2040-6

Weitere Artikel der Ausgabe 1/2012

Breast Cancer Research and Treatment 1/2012 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.